The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Congress 2022 | The role of CALR mutations in the initiation and progression of MPNs
Ann Mullally, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the role of calreticulin (CALR) mutations in the initiation and progression of myeloproliferative neoplasms (MPNs). Whilst it has been shown that CALR mutations alone are sufficient to initiate disease, their role in MPN progression remains unclear. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
